Von Willebrand disease (VWD) is a genetic disorder caused by missing or defective von Willebrand factor (VWF), a clotting protein. VWF binds factor VIII, a key clotting protein, and platelets in blood vessel walls, which help form a platelet plug during the clotting process. Von Willebrand disease is a heterogeneous disorder and is usually classified into two main types, according to inheritance or acquired forms.
DelveInsight's "Von Willebrand Disease (VWD) Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Von Willebrand Disease (VWD) market Size and Share, historical and forecasted epidemiology analysis as well as the Von Willebrand Disease (VWD) market trends in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Von Willebrand Disease (VWD) market report also covers emerging drugs, current treatment practices, Von Willebrand Disease (VWD) market share of the individual therapies, current and forecasted Von Willebrand Disease (VWD) Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current Von Willebrand Disease (VWD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Von Willebrand Disease (VWD) Market Key Facts
According to DelveInsight’s analysis, females are affected more as compared to males, in case of Von Willebrand disease (VWD) in the 7MM.
According to DelveInsight analysis, the total diagnosed prevalent population of VWD in seven major markets was 33,758 in 2017.
Among the 7MM, the lowest prevalent population of VWD was recorded in Japan.
Von Willebrand Disease (VWD) Market Size And Share Analysis
The Von Willebrand Disease (VWD) market size is expected to increase in the coming years owing to the
Increase in the prevalent population of VWD patients in the 7MM. Raising Awareness, Regulatory Approvals and Pediatric Population are some of the key factors expected to drive the Von Willebrand disease (VWD) market forward in the coming years.
The Von Willebrand Disease (VWD) market analysis report helps to build the detailed comprehension of the historic, current and forecasted Von Willebrand Disease (VWD) market trends by evaluating the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Von Willebrand Disease (VWD) market Size and Share analysis of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Von Willebrand Disease (VWD) Epidemiology
The Von Willebrand Disease (VWD) epidemiology analysis covers insights about historical and current Von Willebrand Disease (VWD) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Von Willebrand Disease (VWD) Drugs Uptake and Key Market Players
The Von Willebrand Disease (VWD) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Von Willebrand Disease (VWD) market or expected to get launched in the market during the study period. The analysis covers Von Willebrand Disease (VWD) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Some of the key players in the Von Willebrand Disease (VWD) market includes:
Shire
CSL Behring
Octapharma
LFB Biomedicaments
Ferring Pharmaceuticals
Grifols Biological Inc.
And many others.
For more information on Von Willebrand disease (VWD) Market, visit:
https://www.delveinsight.com/report-store/von-willebrand-disease-vwd-market